Despite Strategic Review, Biogen Idec To Remain Independent
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech has not received “any definitive offers.”
You may also be interested in...
Biogen’s RA Long Shot Fails In Phase IIb
TNF cytokine blocker could work in other diseases.
Biogen’s RA Long Shot Fails In Phase IIb
TNF cytokine blocker could work in other diseases.
Icahn Wins Access To Biogen Idec Documents
Delaware judge grants the billionaire shareholder access to records relating to Biogen’s attempted sale of the company but says they must remain confidential.